Garewal H S, Durie B G
Scand J Haematol. 1985 Nov;35(5):497-500. doi: 10.1111/j.1600-0609.1985.tb02818.x.
11 courses of EACA were given to 9 acutely ill, severely thrombocytopenic patients (platelet count less than 20 X 10(9)/l). 6 patients were being treated for acute leukaemia while 1 each had cyclical amegakaryocytic thrombocytopenia, dysmyelopoietic syndrome and advanced chronic lymphocytic leukaemia. 8 were refractory to HLA-matched platelets and 1 refused blood product transfusion. All had simultaneous major medical complications such as infection and granulocytopenia. The highest dose of EACA used was 24 mg/d. Improvement in haemostasis was noted in all patients with successful control of epistaxis in 1, control of gastrointestinal bleeding in 3 and lack of significant bleeding for 4-29 d in the remaining 5 patients. The only toxicity was dose-related nausea. Since this patient group was at extremely high risk for haemorrhage, we conclude that EACA is safe and useful in the management of thrombocytopenia including that occurring during leukaemic induction.
对9例急性病、严重血小板减少症患者（血小板计数低于20×10⁹/L）给予了11个疗程的6-氨基己酸（EACA）治疗。6例患者正在接受急性白血病治疗，而另外1例分别患有周期性无巨核细胞性血小板减少症、骨髓生成异常综合征和晚期慢性淋巴细胞白血病。8例对人类白细胞抗原（HLA）匹配的血小板治疗无效，1例拒绝输血制品。所有患者均同时伴有严重的内科并发症，如感染和粒细胞减少症。使用的EACA最高剂量为24mg/d。所有患者的止血情况均有改善，1例鼻出血得到成功控制，3例胃肠道出血得到控制，其余5例在4-29天内无明显出血。唯一的毒性反应是与剂量相关的恶心。由于该患者群体出血风险极高，我们得出结论，EACA在治疗血小板减少症（包括白血病诱导期出现的血小板减少症）方面是安全且有效的。
